KLS-1: A Supercharged Zinc Therapy for Oncology Patients

August, 2025

SAFE HARBOR STATEMENT

THE FOLLOWING PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE FEDERAL PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995, CONVEYING THE MANAGEMENT EXPECTATIONS AS TO THE FUTURE BUSINESS PERFORMANCE OF THE COMPANY BASED ON PLANS, ESTIMATES, AND PROJECTIONS AT THE TIME SUCH STATEMENTS ARE MADE. THE FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PRESENTATION MAY BE IDENTIFIED BY THE USE OF WORDS SUCH AS “ANTICIPATE,” “EXPECT,” “BELIEVE,” “WILL,” “MAY,” “SHOULD,” “ESTIMATE,” “PROJECT,” “OUTLOOK,” “FORECAST,” “CANDIDATE” OR OTHER SIMILAR WORDS, AND INCLUDE, WITHOUT LIMITATION, STATEMENTS REGARDING THE ISSUER’S EXPECTATIONS REGARDING TIMELINES AND EXPECTATIONS OF CURRENT OR FUTURE CLINICAL TRIALS. FORWARD-LOOKING STATEMENTS ARE BASED ON THE ISSUER’S CURRENT EXPECTATIONS AND ARE SUBJECT TO INHERENT UNCERTAINTIES, RISKS AND ASSUMPTIONS THAT ARE DIFFICULT TO PREDICT. CERTAIN FORWARD-LOOKING STATEMENTS ARE BASED ON ASSUMPTIONS AS TO FUTURE EVENTS THAT MAY NOT PROVE TO BE ACCURATE, INCLUDING BUT NOT LIMITED TO TIMELINES OF CLINICAL TRIALS AND ANTICIPATED MEETINGS WITH AND/OR PRESENTATION TO THE FDA, WHICH MAY BE DELAYED. THE FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PRESENTATION INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES, INCLUDING, WITHOUT LIMITATION, THE ISSUER’S ABILITY TO PERFORM ITS PLANS, DEGREE OF COMPETITION IN APPLICABLE MARKETS AND INDUSTRIES, LACK OF OPERATING HISTORY, OPERATING LOSSES AND PROFITS, THE NEEDS FOR ADDITIONAL CAPITAL, THE DEPENDENCY UPON QUALIFIED PERSONNEL, THE ENVIRONMENTAL AND OTHER REGULATIONS, ENGAGING STRATEGIC ALLIANCES, AND OTHER RISKS THAT ARE DETAILED IN THE COMPANY’S PRIVATE PLACEMENT MEMORANDUMS. THESE RISKS AND UNCERTAINTIES COULD CAUSE THE COMPANY’S ACTUAL PERFORMANCE TO DIFFER MATERIALLY FROM THE PROJECTED PERFORMANCE EXPRESSED OR IMPLIED IN THIS PRESENTATION. PAST PERFORMANCE DOES NOT GUARANTEE FUTURE SUCCESS. ALL INVESTORS ARE ENCOURAGED TO CONDUCT THEIR OWN INVESTIGATION AFTER THE REVIEW OF THIS PRESENTATION. THE ISSUER UNDERTAKES NO OBLIGATION TO UPDATE OR REVISE ANY FORWARD-LOOKING STATEMENTS, WHETHER RESULTING FROM NEW INFORMATION, FUTURE EVENTS OR OTHERWISE, EXCEPT AS REQUIRED BY THE APPLICABLE LAW. THE FOLLOWING PRESENTATION IS NOT A LEGALLY BINDING DOCUMENT.

This presentation discusses our product candidates that are in early-stage clinical and preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). No representations are made as to the safety or effectiveness of these product candidates for the uses for which they are being studied. There is no assurance that either product candidate will proceed through development or will receive FDA approval for marketing.

Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this presentation may appear without the® or symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.

Metallomix™

Metals and the metallome are central to human health
Metals act as structural, catalytic, regulatory, and signaling elements in biology

Oxygen Transport (hemoglobin, myoglobin)

Energy production Anti-oxidant defence

Protein synthesis DNA repair

Nerve health Muscle function

Bone and teath health Heart & vascular health

An imbalance in metalls, both deficiency and overload contribute to diseases

We make medicines targeting zinc-dependent cellular functions

Many cancers are zinc-dysregulated

so are cardiovascular diseases (coronary artery disease, myocardial infarction...),

autoimmune diseases (ALS, MS, Friedrich's ataxia...),

and metabolic disfunctions (diabetes, NASH, obesity...)







WHAT IS KLS-1?

KLS-1 is isotopically modified zinc diaspartate



Aiming to improve survival rates

- Initial safety in humans established
- Makes chemotherapy more effective
- Reduces treatment-related side effects
- Reduces tumor metastasis invasion
- Active against multi-tumor types

64 Zinc Enriched Precision Medicine Platform

5 Issued **composition of matter** and **methods of use** patents (Exp. 2035-2049)

68 Pending **indication-specific** patent applications including international counterparts (PCT)

16+ Provisional patent applications

Isotopically-natural zinc aspartate covered by our patents pending

SUPERCHARGED ZINC IN KLS-1: WHAT'S DIFFERENT?

Isotopically-Modified Zinc
used in KLS-1 synthesis

Natural Zinc



Attacking aggressive cancers where it hurts them - the depleted light zinc

- Light 64Zn atoms enriched to exceed 99%
- Isotope effects enhance cancer cell death, metastasis suppression
- Reduces systemic and local inflammation and stress
- Replenishing the isotopically light zinc depleted in/by the target cells
- Disease-modifying effect leading to rebuilding a healthy tissue

EARLY SUCCESS

In lab tests, KLS-1 killed cancer cells more effectively than regular zinc



KLS-1 administered sequentially to dacarbazine, doxorubicin, paclitaxel, and vinorelbine resulted in a significant synergistic effect.

Effective Dose (IC50) [KLS1 administered sequential to chemo agent]	% Surviving Malignant Cells (monotherapy)	% Surviving Malignant Cells (combotherapy)	% Improved Efficacy
KLS-1, 5 mcg/ml	27.2%		
Dacarbazine, 7.5 mcg/ml	41.0%	2.1%	1464% (~14x)
Doxorubicin, 150 ng/ml	91.0%	6.0%	1516% (~15x)
Paclitaxel, 1 ng/ml	98.0%	7.8%	1256% (~12x)
Vinorelbine, 1 ng/ml	85.2%	7.8%	1092% (~11x)
Cisplatin, 1 mcg/ml	31.0%	21.0%	147% (~1.5x)

In mice, a single dose of KLS-1 reduced tumors

KLS-1's Anti-Metastic Effect

Administration of KLS-1 suppressed metastases into lungs in mouse melanoma model B16. This experiment shows that KLS-1 therapy may be used for prevention of metastases in human melanoma



L1210 Leukemia Model

Cytotoxic Effect of KLS-1



A. L1210 Control B. L1210 + $^{64}Zn_e$(Asp)

Experimental animals on Day 14 after KLS-1 injection into tumor

A single injection of KLS-1 led to a significant antitumor effect in experimental model of mice melanoma, B16, accompanied by a revival of skin tissue as evidenced by hair growth.



Control mouse 3 weeks post treatment | KLS1 single injection 3 weeks post treatment | KLS1 single injection 5 weeks post treatment

These pre-clinical results warrant strong confidence to move into human trials

THE TEAM BEHIND THE INNOVATION FLAG

Founder, President, CSO & Director

Max Temnik, PhD

Investor in several biotech startups, experienced entrepreneur with multiple business ventures, expert in chemistry.

Co-Founder & CEO

Sergei Petukhov, DVM, MSc

Distinguished venture capitalist in the biotech sector, noted for securing "unicorn" IPO exits and M&As, serving as a board member for various biotech companies.

Co-Founder, EVP & Interim CFO

Sergey Gurin, MBA

Accomplished serial entrepreneur, investor and inventor with proficiency in management, business growth, intellectual properties, and securities offerings.

VP, Product Development, Oncology, Neurology

Santosh Kesari, MD, PhD

Leading neuro-oncologist in the U.S., distinguished by extensive research and development expertise coupled with practical experience.

VP, Product Development, Internal Diseases

Leonid Magilenko, MD

Boaard-certified physician in internal medicine with 25+ years of clinical experience.

Board Member

Walter Olesiak, BS, MBA

Over 28 years experience in business development, healthcare consulting and venture investment with Remiges Ventures, Mitsui, Cambridge Pharma Consultancy (an IMS Health company), Genzyme Japan and SRL, Inc.

Chair of Advisory Board

Al Beardsley, PhD

30+ years of creating and leading complex, highly successful public and private sector biopharma companies including Galera, MSDC, Kereos, President & CEO Cirius Therapeutics

Isotope Effects in Biological Organisms

Roman Zubarev, PhD

Professor of medicinal proteomics in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet.

Regulatory Affairs and Compliance

Andreia Collier, MSc

Over 80 successful INDs and 60 NDAs with the FDA, in oncology, dermatology and cardiology divisions; regulatory approvals in Europe, Australia, Latin America, Japan and Asia; worked at Gilead, BTG, Johnson & Johnson and Merck.

Analytical/Bioanalytical Chemistry

James Blackledge, PhD

Expert in biological mass spectroscopy, 20+ years in pharmaceutical drug development, founder of Capella Imaging, R&D at BMS, Parke-Davis, Kereos, Inc, Mallinckrodt Pharmaceuticals and Galera Therapeutics.

Thank you!

Dr. Sergei Petukhov, CEO
spetukhov@metallomix.com

www.metallomix.com